At the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO), data were presented from a phase II investigator-sponsored trial paclitaxel poliglumex (OPAXIO™, CT-2103) in combination with capecitabine in first-line treatment of patients with metastatic breast cancer (MBC).
The goals of the study were to explore the tolerability and objective anti-tumor response rate as well as the disease-free progression and survival times of the regimen.
Although the study did not meet its pre-defined endpoint of 21 or more responses in the first 41 patients, 20 patients (42 percent) of the 48 evaluable patients demonstrated a confirmed tumor response, including two complete responses and 18 partial responses.
The authors concluded the combination of paclitaxel poliglumex and capecitabine was well tolerated and active in MBC. OPAXIO is being developed by Cell Therapeutics, Inc.
"Given the convenient dosing schedule, a 15 minute infusion every 3 weeks, as well as no requirement for premedications and minimal hair loss associated with OPAXIO compared to other taxanes, the goal of the study was to determine if OPAXIO combined with capecitabine, an oral chemotherapy agent, as first- line therapy in metastatic breast cancer would prove to be an active and relatively well tolerated regimen," said Jack W. Singer, M.D., Chief Medical Officer of CTI.
"The severe toxicities included neutropenia without neutropenic fever, neuropathy, and cutaneous toxicity that is most likely from capecitabine. We agree with the authors conclusions that the combination of OPAXIO and capecitabine had efficacy similar to other taxane/capecitabine combinations and was well tolerated and active in this patient population."